Selenium is a non-metallic chemical
Introduction
Micronutrient supplementation has shown beneficial effects among the human immunodeficiency virus (HIV) infected population 1,2 and there has been increasing interest in supplementation as a therapeutic strategy. Selenium is a non-metallic chemical element deriving from both vegetables and animal products, in particular seafood, liver and cereals. 3 Since the late 1960's, its role on humans' health has been extensively investigated.
Selenium is a key component of several human selenoproteins and mostly involved in redox reactions. 4 It is required for the activity of the enzyme glutathione peroxidase (GPX), a main intracellular antioxidant, that acts to prevent oxidation-induced cellular damage. 5 Chronic exposure to high levels of selenium may be associated with several health problems in humans such as nail and hair loss, gastroenteritis and dermatitis but the most important health effects are related to the deficient state. 6 The normal ranges of serum selenium plasma levels in adults are 1.1 to 2.5 µmol/L in blood and 0.75 to 1.35 mmol/L. The minimum daily intake of selenium is recommended at 30 µg. 7 Selenium deficiency in humans is associated with an increased incidence of cancer, cardiomyopathy (including Keshan disease), a deforming osteoarthropathy (Kashin-Beck disease), male sub-fertility, liver dysfunction, mood disorders, skeletal muscle disorders, impaired thyroid hormone metabolism, impaired immune function, progression of HIV infection and mortality. The first studies were published on the role of selenium in HIV-infected patients in 1989. The aim of this review is to summarise the evidence regarding the relationship between selenium and HIV infection.
Materials and Methods
We carried out a literature review of published studies that evaluated the relationship between serum/plasma selenium status or selenium supplementation and HIV disease in human subjects. The search was performed through the PubMed database and restricted to full articles published up to September 2009, irrespective of language. No attempt was made to obtain information about unpublished studies.
Index search terms included the Medical Subjects Heading selenium, HIV, AIDS, immunodeficiency, malnutrition, co-infection, opportunistic infections, AIDS progression, AIDSrelated neoplasm, viral load, CD4, AIDS stage.
Studies were considered eligible if they presented data pertaining to the relationship between selenium and HIV disease. Reviews, editorials, case reports and literature regarding animal or in vitro studies were excluded.
We did not include results concerning the relationship between selenium and HIV genital shedding.
Results
Our literature search identified 195 articles. Among these we found 33 studies that met our search criteria. In summary, we found 13 cross-sectional studies, 11 prospective observational studies and 9 clinical trials.
Selenium and sero-status of HIV
The possible relationship between serum selenium levels and the sero-status of HIV has been analysed in 12 studies. 18, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] The majority of these reported a significant association between HIV infection and low serum selenium levels. [30] [31] [32] [33] [34] [35] [36] [37] [38] However, three studies comparing HIV-positive to HIV-negative subjects did not find a significant relationship between HIV-infection and selenium deficiency. 18, [39] [40] It is possible that these studies failed to demonstrate a significant association due to small sample sizes 39, 40 and the inclusion of severely malnourished subjects in both the HIV-positive and HIV-negative study groups. 18 
Selenium and HIV disease stage/disease progression
An association between selenium levels and HIV disease stage (including CD4 cell counts, opportunistic infections, AIDS-related neoplasm and viral load) has been reported by seven authors. [14] [15] [16] [17] [19] [20] [21] Cirelli et al. measured serum selenium concentration in four groups of HIV-infected patients: symptom-free subjects, persistent generalized lymphadenopathy (PGL), AIDS related complex (ARG) and AIDS. Serum selenium concentrations were significantly higher in symptom-free HIV positive subjects as compared to the other three groups.
14 Similarly, Constans et al. observed that serum levels of selenium were lower in patients with a count Se had no effect on maternal mortality from recruitment until 6 mo after delivery 15 Another study reported that opportunistic infections occurred more frequently among patients with lower serum selenium concentration. 16 In a crosssectional study on 104 HIV-infected individuals Look et al. reported that mean serum selenium levels were significantly lower in patients at CDC HIV stage II and III as compared to healthy subjects and to HIV stage I patients. 17 In addition, three clinical trials reported a slower decline in CD4 or an increase in CD4 cell counts in patients receiving oral selenium supplementation and these are briefly described below. [19] [20] [21] Burbano et al. conducted a randomized, double-blind, placebo-controlled trial on 186 HIVinfected individuals and showed that the placebo group had a more rapid decline in CD4 count than the selenium-supplemented group. 19 A further randomized, double-blind, placebo-controlled supplementation trial (micro nutrients + 200 mg/day of selenium) designed by McClelland et al., involving 400 pregnant HIV positive women in Kenya, showed that the selenium-supplemented group had higher CD4 levels than the placebo group. 20 Hurwitz et al. administered either supplementation with selenium (200 mg/day) or placebo to 174 HIV subjects for 9 months. At the end of the follow-up period, an higher increase in CD4 count was observed among selenium responders (individuals whose mean serum selenium concentration changed more than 3 standard deviations above the mean serum selenium concentration change of the placebo group) than that recorded in the placebo and selenium non-responder groups. Authors performed an analysis to examine if the effect on CD4 count was mediated by the viral load change. Interestingly, a model with several covariates (including HIV disease stage, antiretroviral treatment and adherence to it) confirmed that, in this study, selenium treated patients had a significant decrease in HIV viral load. 21 Seven studies did not demonstrate a significant relationship between selenium levels or supplementation and CD4 cell count or disease status. 27, [41] [42] [43] [44] [45] However, Rousseau et al. failed to find a relationship between selenium levels and CD4 cell count or disease status in a study which looked at patients treated with highly active antiretroviral therapy (HAART). This may suggest that the rapid improvement in the immune status of the patients taking antiretroviral therapy, may be masking any effect of selenium supplementation or adequate plasma selenium levels. 46 The majority of studies that investigated for a relationship between either plasma or serum selenium concentration or selenium supplementation and plasma HIV viral load, failed to find a significant association. 20, 27, 38, 44, 47 Only one supplementation trial reported that seleniumresponders had slower progession of HIV viral burden than the placebo or selenium nonresponders group. 21 
Selenium and mortality in HIVinfected subjects
Five studies evaluated the role of selenium on mortality in HIV-infected subjects. 15, 22, 25, 26, 48 Allavena et al. analyzed the relationship between serum selenium levels in 80 HIV seropositive patients at stage IV of infection (CDC classification) treated with zidovudine (AZT) and mortality within one year. They observed that the patients who died had significantly lower selenium values. 22 In a one-year prospective study on 95 HIV positive subjects, Constans et al. found that death was significantly associated with low serum selenium levels. 15 Baum et al. longitudinally evaluated 125 HIV positive intravenous drug users for 3.5 years: selenium deficiency was significantly associated with mortality. 25 In another study, Campa et al. observed 24 HIV positive children, for a five-year period and found that selenium deficiency was an independent risk factor for HIV-related mortality. 26 Only one supplementation trial did not observe an effect of selenium on mortality. 48 
Selenium and HIV co-infections
Only two studies have been carried out to investigate the relationship between selenium levels and co-infected HIV positive individuals. 17, 49 Look et al., in a cross-sectional study, compared serum selenium levels among HIVinfected patients co-infected with hepatitis C virus (HCV) and subjects infected with HIV only. HCV co-infected patients showed significantly lower selenium concentrations. 17 Finally, Shor-Posner et al. demonstrated that lower levels of selenium significantly increased the risk of developing mycobacterial disease among HIV-infected individuals. 49 Selenium and cardiovascular involvement in HIV-infected subjects Selenium seems to also play a role in the development of cardiac dysfunction among HIV-positive subjects. Two studies investigated this relationship and are described below. 50, 51 Zazzo et al. prospectively evaluated the effect of selenium supplementation in 10 consecutive patients with both acquired immune deficiency syndrome (AIDS) and non-obstructive cardiomyopathy. Each patient received sodium selenite orally, 800 mg/day for 15 days and 400 mg/day for 8 days. Eight of these patients were found to have low plasma selenium levels before treatment yet six showed a return to a normal left ventricular shortening fraction within 21 days. One patient died on the 15 th day of treatment and one had a thiamin deficiency. 50 Twagirumukiza et al. conducted a prospective multicenter study of 416 HIV positive Rwandan patients who were not receiving HAART and did not have a previously documented history of cardiovascular disease. Clinical examination, biochemical tests and echocardiography was carried out on all those enrolled in the study. Investigations showed that 71 (17.7%) patients had dilated cardiomyopathy and a low plasma level of selenium was significantly associated with the development of cardiomyopathy. 51 Selenium and hospital admissions in HIV infected subjects A randomized, double-blind, placebo-controlled study evaluated the role of selenium supplementation on preventing hospital admission in patients with HIV infection, attending outpatient clinics. 19 The trial showed a decrease in total hospital admission rates, percent of hospitalization and cost for hospitalization in the selenium-receiving group compared with the placebo group.
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Discussion
Selenium is recognized to have an important role in both immunologic function and antioxidant defense mechanisms. Evidence suggests that oxidative stress contributes to the pathogenesis of HIV infection; in fact several studies have indicated that the apoptosis of CD4 cells contributing to HIV progression does not result solely from HIV infection, but largely from antioxidant imbalances in the host. [52] [53] [54] It has been reported that selenium supplementation has a positive effect on oxidative stress in HIV-infected individuals. 32 Moreover, studies show that selenium is vital to cell-mediated immunity and B-cell function. 55 According to the majority of published studies, HIV infection is associated with lower serum selenium concentration. [30] [31] [32] [33] [34] [35] [36] [37] [38] Nutritional deficiencies are common in HIV-infected individuals 56, 57 and are caused by several factors: the oxidative state induced by the virus, malabsorption, altered metabolism, gut infection, altered gut barrier function, and the hypermetabolic state produced by chronic HIV infection. [58] [59] [60] It has also been suggested that a possible cause of selenium depletion among HIV positive subjects is the utilization of selenium by HIV-1 virus to produce its own selenoenzymes. 61, 62 In our literature review, three studies did not find a significant relationship between blood selenium concentrations when HIV seropositive and HIV seronegative subjects were compared. 18, 39, 40 It is interesting to note that in a study conducted by Look et al., when comparing advanced stage HIV subjects with uninfected subjects, the former group had significant lower selenium levels. Whereas there was no difference in blood selenium levels if asymptomatic HIV-positive subjects were compared with uninfected subjects. 17 These findings suggest that HIV infection alone is not the sole factor involved but perhaps it is the stage of disease that has a larger impact on selenium level.
Many authors report a significant relationship between CD4 cell count, opportunistic infections, HIV stage and selenium levels, whereas the association with HIV viral load is much more controversial.
Regarding the role of selenium in HIV-HCV co-infection, co-infected subjects usually have a higher levels of oxidative-stress which could explain the progressive lack of endogenous antioxidants and the subsequent decrease in selenium levels. As such, infection with more than one virus may cause an higher selenium depletion.
Data from the literature, indicates that cardiac tissue selenium levels are lower in AIDS patients with cardiomyopathy as compared to non-AIDS controls. 51 Indeed, low plasma levels of selenium are associated with the development of cardiomyopathy in HIV positive individuals who are not receiving HAART. 63, 64 Two further studies showed an improvement of the patient's left ventricular shortening fraction after selenium supplementation. 50, 65 The role of selenium in the pathogenesis of cardiac diseases has been suggested yet. Selenium deficiency has been strongly implicated in the pathogenesis of Keshan disease, a dilated congestive cardiomyopathy endemic to certain mountainous areas of China.
9,29 A similar cardiomyopathy has been described in patients on long-term total parenteral nutrition who became selenium deficient. 10, 56, 57 In conclusion, although HAART has remarkably improved the survival of HIV-infected individuals, selenium supplementation could yet have a role in slowing the disease progression, by reducing the incidence of opportunistic infections and HIV-associated mortality. This may have a particularly useful application in patients living in countries with poor economic resources. However, it is not possible to give an exact indication on the use of selenium in clinical practice.
The role of selenium in cardiovascular diseases seems interesting and deserve further investigations. Since the oxidative stress from free radicals may promote heart disease, selenium, because of its antioxidant properties, may help limit the oxidation of LDL cholesterol and thereby help to prevent coronary artery disease. A recent meta-analysis showed that selenium concentrations were inversely associated with coronary heart disease risk in observational studies but findings from randomized trials that addressed the cardiovascular efficacy of selenium supplementation are still inconclusive. 66 HIV-positive patients, especially those living in resource replete settings, are now at greater risk of cardiovascular diseases, due to the effects of HAART and to the longer life-expectancy. The evaluation of the effect of selenium supplementation on cardiovascular risk among HIV-positive subjects, especially among those taking HAART, would be useful.
It is important to underscore that our study simply reviewed the available evidence on the effect of selenium in HIV infected subjects. Since we have not performed any statistical analysis we are not able neither to state the exact relationship between selenium and HIV disease nor to clearly define the role of selenium in the disease progression and the HIVrelated mortality. Moreover published studies on this topic have several limitations. First, regarding selenium supplementation, only three randomized trials aimed to assess its effect on HIV viral load or CD4 count were performed. Most of included studies were cohort or case-control studies, with the known limitation of these studies. Second, in two trials, selenium was administered in association with other supplements, hampering the assessment of the effect due to selenium. Third, in most of included studies, an adjustment for principal confounders (i.e. CD4 mean count, HIV viral load, antiretroviral therapy, presence of factors that could reduce selenium adsorption) was not performed. Finally, several studies were performed in the era that preceded the introduction of highly active antiretroviral therapies or were conducted in resourcepoor settings, involving populations with limited or no access to HAART or patients taking non-standardised antiretroviral regimes.
Further randomized clinical trials, enrolling an adequate number of HIV infected subjects, are needed to clarify the role of selenium supplementation both in HIV naïve-patients and in those treated with HAART.
